Dofetilide: A new class III antiarrhythmic agent

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 1, 2007, Pages 9-19

  Roukoz, Henri ^a   Saliba, Walid ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiarrhythmic agents; Arrhythmia; Atrial flutter; Dofetilide; Fibrillation

Indexed keywords

AMILORIDE; AMIODARONE; AMLODIPINE; ANTACID AGENT; ANTIARRHYTHMIC AGENT; CIMETIDINE; COTRIMOXAZOLE; CREATININE; DIGOXIN; DOFETILIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; ION CHANNEL; KETOCONAZOLE; MEGESTROL; METFORMIN; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; PLACEBO; PROCHLORPERAZINE; PROPAFENONE; PROPRANOLOL; SOTALOL; THEOPHYLLINE; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ABDOMINAL DISCOMFORT; ACTION POTENTIAL; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART MUSCLE CELL; HEART PROARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HOSPITAL CARE; HUMAN; INSOMNIA; MORTALITY; NAUSEA; NONHUMAN; PATIENT MONITORING; PATIENT SELECTION; QT INTERVAL; REENTRY TACHYCARDIA; REFRACTORY PERIOD; RISK FACTOR; RISK REDUCTION; SINUS RHYTHM; SUDDEN DEATH; THORAX PAIN; TORSADE DES POINTES;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; HEART FAILURE, CONGESTIVE; HUMANS; PHENETHYLAMINES; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES; TACHYCARDIA, SUPRAVENTRICULAR; TORSADES DE POINTES; VENTRICULAR FUNCTION, LEFT;

EID: 33846473656     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.1.9     Document Type: Article

References (60)

1. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: A systematic review of randomized controlled trials. Arch. Intern. Med. 166, 719-728 (2006).
2. Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 324, 781-788 (1991).
3. Effect of the antiarrythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Supression Trial II investigators. N. Engl. J. Med. 327, 227-233 (1992).
4. Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348, 7-12 (1996).
5. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82, 1106-1116 (1990).
6. Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin. Pharm. 12, 721-735 (1993).
7. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350, 1417-1424 (1997).
8. Gwilt M, Arrowsmith JE, Blackburn KJ et al. UK-68,798: A novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther. 256, 318-324 (1991).
9. Pfizer. March 2004.
10. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am. J. Cardiol. 69, 513-517 (1992).
11. Baskin EP, Lynch JJ, Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J. Pharmacol. Exp. Ther. 285, 135-142 (1998).
12. Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin JP, Pollard CE. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br. J. Pharmacol. 142, 1255-1264 (2004).
13. Demolis JL, Funck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 94, 1592-1599 (1996).
14. Yang T, Tande PM, Refsum H. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle. J. Cardiovasc. Pharmacol. 20, 889-894 (1992).
15. Yang T, Tande PM, Lathrop DA, Refsum H. Class III antiarrhythmic action by potassium channel blockade: Dofetilide attenuates hypoxia induced electromechanical changes. Cardiovasc. Res. 26, 1109-1115 (1992).
16. Kovacs A, Szenasi G. Effects of Dofetilide and EGIS-7229, an Antiarrhythmic Agent Possessing Class III, IV, and IB Activities, on Myocardial Refractoriness in Hyperkalemia, Hypokalemia, and During beta-Adrenergic Activation in the Rabbit Papillary Muscle In Vitro. J. Pharmacol. Sci. 100, 303-309 (2006).
17. Ducroq J, Rouet R, Salle L et al. Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. Eur. J. Pharmacol. 532, 279-289 (2006).
18. Rouet R, Picard S, Libersa C, Ghandanfar M, Alabaster CT, Gerard JL. Electrophysiological effects of dofetilide in an in vitro model of "border zone" between normal and and ischemic/reperfused myocardium. Circulation 101, 86-93 (2000).
19. Wallace AA, Stupienski RF, 3rd, Brookes LM, Selnick HG, Claremon DA, Lynch JJ, Jr. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J. Cardiovasc. Pharmacol. 18, 687-695 (1991).
20. Rousseau MF, Massart PE, van Eyll C et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am. J. Cardiol. 87, 1250-1254 (2001).
21. DeCara JM, Pollak A, Dubrey S, Al E. Positive atrial inotropic effects of dofetilide following cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. 31, 432A-433A (19980.
22. Tham TC, MacLennan BA, Burke MT, Harron DW. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J. Cardiovasc. Pharmacol. 21, 507-512 (1993).
23. Gardner MJ, DeMattos SB, Schumacher DA et al. the effect of food on the PK and PD of Dofetilide in healthy male and female subjects [ABSTRACT]. J. Clin. Pharmacol. 37, 874 (1997).
24. Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica 22, 709-719 (1992).
25. Walker DK, Alabaster CT, Congrave GS et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug. Metab. Dispos. 24, 447-455 (1996).
26. Noveck R, Vincent J, Gardner MJ et al. The safety, toleration, PK and PD of dofetilide in patients with hepatic impairment [Abstract). Br. J. Clin. Pharmacol. 38, 170P (1994).
27. Sedgwick M, Rasmussen HS, Walker D, Cobbe SM. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrythmic drug. Br. J. Clin. Pharmacol. 31, 515-519 (1991).
28. Nichols DJ, Abel S, Eve MD. The effect of cimetidine (100mg BID and 400mg BID) and ranitidine on the PK and PD of a single dose of dofetilide [ABSTRACT]. J. Clin. Pharmacol, 37, 877 (1997).
29. Kleinermans DF, Nichols DJ, Dalrymple I. Effect of dofetillide on the pharmacokinetics of digoxin. Am. J. Cardiol. 87, 248-250 (2001).
30. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155, 469-473 (1995).
31. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22, 983-988 (1991).
32. Greenbaum RA. Meeting Highlights: Highlights of the 71st scientific sessions of the american heart association. The EMERALD trial. Circulation 99, 2486-2491 (1999).
33. Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med. 341, 857-865 (1999).
34. Kober L, Bloch Thomsen PE, Moller M et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet 356, 2052-2058 (2000).
35. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104, 292-296 (2001).
36. Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102, 2385-2390 (2000).
37. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J. Am. Coll. Cardiol. 29, 385-390 (1997).
38. Norgaard BL, Wachtell K, Christensen PD et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J. 137, 1062-1069 (1999).
39. Bianconi L, Castro A, Dinelli M et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur. Heart J. 21, 1265-1273 (2000).
40. Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int. J. Cardiol. 58, 135-140 (1997).
41. Pfizer. Briefing documents for Tyksin capsules, FDA cardiorenal Divison Advisory Committee. January 1998.
42. Tendera M, Wnuk-Wojnar AM, Kulakowski P et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo. Am. Heart J. 2001;142:93-98.
43. Kobayashi Y, Atarashi H, Ino T et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J. Cardiovasc. Pharmacol. 30, 367-373 (1997).
44. Krahn AD, Klein GJ, Yee R. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing. Clin. Electrophysiol. 24, 1258-1260 (2001).
45. Cobbe SM, Campbell RW, Camm AJ et al. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart 86:522-526 (2001).
46. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N. Engl. J. Med. 329, 452-458 (1993).
47. Bashir Y, Thomsen PE, Kingma JH et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am. J. Cardiol. 76, 1040-1044 (1995).
48. Echt DS, Lee JT, Murray KT et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophysiol. 6, 687-699 (1995).
49. Gremillion ST, Echt DS, Smith NA et al. Beneficial effects of intravenous dofetilide in patients undergoing ventricular defribillation testing. Circulation 86(suppl), I264 (1992).
50. Davis DR, Beatch GN, Dickenson DR, Tang AS. Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Can. J. Cardiol. 15, 193-200 (1999).
51. Echt DS, Gremillion ST, Lee JT et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving ICD's. J. Cardiovasc. Electrophysiol. 5, 752-760 (1994).
52. Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am. Heart J. 138:994-997 (1999).
53. Brendorp B, Elming H, Jun L et al. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 103, 1422-1427 (2001).
54. Pratt CM, Camm AJ, Cooper W et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: Why did patients die? Am. J. Cardiol. 81, 869-876 (1998).
55. Julian D, Camm A, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667-674 (1997).
56. Cairns J, Connolly S, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349, 675-682 (1997).
57. Karam R. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am. J. Cardiol. 81(6A), 40D-46D (1998).
58. Aimond F. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J. Pharmacol. Exp. Ther. 292(1), 415-412 (2000).
59. Reiffel JA. Atypical proarrhythmia with dofetilide: Monomorphic VT and exercise-induced torsade de pointes. Pacing and clinical electrophysiology: PACE 28, 877-879 (2005).
60. Fuster V. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 48, e149-246 (2006).